Core Viewpoint - Orion Group Holdings, Inc. has announced the dual listing of its common stock on NYSE Texas, maintaining its primary listing on the New York Stock Exchange with the same ticker symbol "ORN" [1] Group 1: Company Overview - Orion Group Holdings is a leading specialty construction company serving the infrastructure, industrial, and building sectors [3] - The company provides services both on and off the water across the continental United States, Alaska, Hawaii, Canada, and the Caribbean Basin [3] - Orion's marine segment offers construction and dredging services related to marine transportation facility construction, marine pipeline construction, and environmental dredging [3] - The concrete segment provides turnkey concrete construction services for large commercial and structural projects [3] Group 2: Leadership Commentary - The CEO of Orion expressed pride in being among the founding members listed on NYSE Texas, highlighting the company's long-standing roots in Texas and its alignment with pro-growth values [2] - The Chief Development Officer of the NYSE Group welcomed Orion to NYSE Texas, emphasizing the state's business-friendly climate as a compelling platform for forward-looking companies [2]

Management to Host Webcast/Conference Call on Thursday, June 12, 2025 at 8:00am EDT MONCTON, New Brunswick, May 28, 2025 (GLOBE NEWSWIRE) -- Major Drilling Group International Inc. (TSX: MDI) (the "Company") will release its fourth quarter and fiscal 2025 results for the year ended April 30, 2025, on Wednesday, June 11, 2025 after the markets have closed. Webcast/Conference Call Details Major Drilling Group International Inc. is the world's leading provider of specialized drilling services primarily serving ...

Details of the presentations are as follows: AUVELITY Title: Initiating Dextromethorphan 45 mg - Bupropion 105 mg (AUVELITY) in Patients with Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations Lead Author: Anita Clayton, MD, Wilford W. Spradlin Professor and Chair of Psychiatry & Neurobehavioral Sciences and Professor of Clinical Obstetrics & Gynecology at the University of Virginia Presentation Date and Time: Wednesday, May 28, 11:15 a.m. - 1 p.m. Mountain Standard Time Session Name: P ...

Our OTC LinkAlternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets. NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced that Magna Mining Inc. (TSX-V: NICU; OTCQX: MGMNF), a company engaged in the acquisition, production, d ...

CAMARILLO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Newton Golf Company, Inc. (NASDAQ: NWTG), a technology-driven golf shaft manufacturer, today announced that it has received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market. The confirmation from Nasdaq follows Newton Golf's filing of i ...

SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the "Board") on May 27, 2025 approved a One-for- Thirty (1-for-30) reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company's ...

About 303 Study 303 Study is an open-label, single-arm Phase 2 Study of Plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital, Beijing, China with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical C ...

SOL-1, Ocular's first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the trial continues on track for top-line readout in 1Q 2026 These two complementary trials are intended to form the basis of an NDA submission of AXPAXLI in wet AMD BEDFORD, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced that ...

Core Insights - Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel molecular glue degrader (MGD)-based medicines [3] - The company will have its CEO, Markus Warmuth, participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 [1][2] Company Overview - Monte Rosa is developing highly selective MGD medicines aimed at treating serious diseases in oncology, autoimmune, and inflammatory disease areas [3] - The company's QuEEN™ discovery engine utilizes AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to design MGDs with unprecedented selectivity [3] - Monte Rosa has established a global license agreement with Novartis for VAV1-directed molecular glue degraders and a strategic collaboration with Roche to develop MGDs for cancer and neurological diseases [3]

Core Insights - Generation Bio Co. is focused on developing innovative therapeutics for T cell-driven autoimmune diseases [3] - The company will present at the Jefferies Global Healthcare Conference on June 4, 2025 [1] - A live webcast of the presentation will be available on the company's investor website [2] Company Overview - Generation Bio is developing redosable therapeutics that aim to reprogram T cells in vivo to combat autoimmune diseases [3] - The company utilizes cell-targeted lipid nanoparticles (ctLNP) for selective delivery of small interfering RNA (siRNA) to T cells [3] - This approach targets historically undruggable genes associated with autoimmune diseases, potentially unlocking new treatment avenues [3]